<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121056</url>
  </required_header>
  <id_info>
    <org_study_id>20020145</org_study_id>
    <nct_id>NCT00121056</nct_id>
  </id_info>
  <brief_title>REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations</brief_title>
  <official_title>Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations (REKinDLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Enbrel® or Kineret® will have a positive effect
      on subject functionality as measured by the Health Assessment Questionnaire Disability Index
      (HAQDI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel®</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kineret®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects with active rheumatoid arthritis as defined by ACR criteria
        - Able to start Enbrel® or Kineret® therapy (per the approved product monographs) within
        approximately 30 days of confirmed enrolment Exclusion Criteria: - Active infections at the
        time of initiating Enbrel® or Kineret® therapy - Malignancy other than basal cell carcinoma
        of the skin or, in situ carcinoma of the cervix, within the past 5 years - Known
        hypersensitivity to E. coli derived products - Known hypersensitivity to Enbrel® or any of
        its components - Subjects receiving, or who received:* Enbrel® in the previous 30 days; *
        Remicade® in the previous 3 months; * Humira® in the previous 3 months; * Kineret® in the
        previous 15 days. - Subjects beginning Enbrel® therapy, or treated with prior or current
        treatment using Enbrel® - Subjects beginning Kineret® therapy, or treated with prior or
        current treatment using Kineret® - Treatment with any investigational therapy in the 30
        days prior to enrolment confirmation - Presence of any significant and uncontrolled medical
        condition which, in the investigator's opinion, precludes the use of Enbrel® - Sepsis or at
        risk of septic syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.kineretrx.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>December 4, 2008</last_update_submitted>
  <last_update_submitted_qc>December 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

